KRAS therapies had their break-out moment in 2019, with Amgen’s KRAS inhibitor becoming the first drug of its type to post clinical data last September, demonstrating that it shrank tumors in 90% of lung cancer patients.
Cancer Research UK has launched a new clinical trial of a drug that researchers are hoping could prevent bladder cancers from becoming resistant to chemotherapy.